Moderna Expands Cost-Cutting Program By Up To $1.7 Billion, FDA Approval For Flu/COVID-19 Combo Shot Delayed Into 2026
1. Moderna reported a Q1 EPS loss of $(2.52), better than expected. 2. Quarterly sales were $108 million, down from $167 billion year-ago. 3. Sales decline due to lower vaccination rates and market normalization. 4. New cost efficiency programs project lower operating costs by 2027. 5. Phase 3 data for mRNA-1083 showed progress, but approval delayed.